GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Revenue per Share

Mega Genomics (HKSE:06667) Revenue per Share : HK$0.83 (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Revenue per Share?

Mega Genomics's revenue per share for the six months ended in Jun. 2024 was HK$0.55. Mega Genomics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.83.

Warning Sign:

Mega Genomics Ltd revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Mega Genomics was 13.30% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Mega Genomics's Revenue per Share or its related term are showing as below:

HKSE:06667' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.1   Med: 1.5   Max: 11.1
Current: -8.1

During the past 5 years, Mega Genomics's highest 3-Year average Revenue Per Share Growth Rate was 11.10% per year. The lowest was -8.10% per year. And the median was 1.50% per year.

HKSE:06667's 3-Year Revenue Growth Rate is ranked worse than
72.36% of 199 companies
in the Medical Diagnostics & Research industry
Industry Median: 2 vs HKSE:06667: -8.10

Mega Genomics Revenue per Share Historical Data

The historical data trend for Mega Genomics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Revenue per Share Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
0.58 1.01 2.28 0.79 0.78

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Revenue per Share Get a 7-Day Free Trial Premium Member Only 0.58 0.25 0.49 0.28 0.55

Competitive Comparison of Mega Genomics's Revenue per Share

For the Diagnostics & Research subindustry, Mega Genomics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mega Genomics's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Mega Genomics's PS Ratio falls into.


;
;

Mega Genomics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Mega Genomics's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=165.489/211.767
=0.78

Mega Genomics's Revenue Per Share for the quarter that ended in Jun. 2024 is calculated as

Revenue Per Share (Q: Jun. 2024 )=Revenue (Q: Jun. 2024 )/Shares Outstanding (Diluted Average) (Q: Jun. 2024 )
=115.503/209.637
=0.55

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mega Genomics  (HKSE:06667) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Mega Genomics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Genomics Business Description

Traded in Other Exchanges
N/A
Address
North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
Executives
Dongyin Industrial (shenzhen) Co., Ltd. 2106 Person having a security interest in shares
Dongyin (tianjin) Enterprise Management Consulting Co., Ltd. 2106 Person having a security interest in shares
Dongfu Hetong (tianjin) Equity Investment Fund Partnership Enterprise (limited Partnership) 2106 Person having a security interest in shares
Yurong Technology Limited 2101 Beneficial owner
Dongfu (beijing) Investment Management Co., Ltd. 2106 Person having a security interest in shares
Dong Yin Development (holdings) Limited 2106 Person having a security interest in shares
China Orient Asset Management Co., Ltd. 2106 Person having a security interest in shares
Beijing Dongfu Huitong Investment Management Center (limited Partnership) 2106 Person having a security interest in shares
Guo Meiling 2101 Beneficial owner
Yu Rong 2501 Other
Lin Lin 2101 Beneficial owner
Infinite Galaxy Health Limited 2101 Beneficial owner
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si 2501 Other

Mega Genomics Headlines

No Headlines